Vaccine-induced seroconversion in participants in the North Carolina COVID-19 community Research Partnership.
AuthorFriedman-Klabanoff, DeAnna J
Tjaden, Ashley H
Sanders, John W
Herrington, David M
Wierzba, Thomas F
Berry, Andrea A
MetadataShow full item record
AbstractWell-regulated clinical trials have shown FDA-approved COVID-19 vaccines to be immunogenic and highly efficacious. We evaluated seroconversion rates in adults reporting ≥ 1 dose of an mRNA COVID-19 vaccine in a cohort study of nearly 8000 adults residing in North Carolina to validate immunogenicity using a novel approach: at-home, participant administered point-of-care testing. Overall, 91.4% had documented seroconversion within 75 days of first vaccination (median: 31 days). Participants who were older and male participants were less likely to seroconvert (adults aged 41-65: adjusted hazard ratio [aHR] 0.69 [95% confidence interval (CI): 0.64, 0.73], adults aged 66-95: aHR 0.55 [95% CI: 0.50, 0.60], compared to those 18-40; males: aHR 0.92 [95% CI: 0.87, 0.98], compared to females). Participants with evidence of prior infection were more likely to seroconvert than those without (aHR 1.50 [95% CI: 1.19, 1.88]) and those receiving BNT162b2 were less likely to seroconvert compared to those receiving mRNA-1273 (aHR 0.84 [95% CI: 0.79, 0.90]). Reporting at least one new symptom after first vaccination did not affect time to seroconversion, but participants reporting at least one new symptom after second vaccination were more likely to seroconvert (aHR 1.11 [95% CI: 1.05, 1.17]). This data demonstrates the high community-level immunogenicity of COVID-19 vaccines, albeit with notable differences in older adults, and feasibility of using at-home, participant administered point-of-care testing for community cohort monitoring.
Data AvailibilityResults of the COVID-19 CRP are being disseminated on the study website as well as in publications and presentations in medical journals and at scientific meetings. At end of the study, the databases will be made publicly available in a de-identified manner according to CDC and applicable U.S. Federal policies.
Data / Code Locationhttps://www.covid19communitystudy.org
Rights/TermsCopyright © 2022. Published by Elsevier Ltd.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/19825